上市MEK抑制剂Ⅰ期临床试验数据总结

Abstract
Figure/Table
References (25)
Related Citation (0)

Download: PDF (564 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The mitogen-activated extracellular signal-regulated kinase (MEK) is a dual specificity kinase that selectively phosphorylates serine/threonine and tyrosine residues on target protein. MEK has become an attractive target because inhibiting its activity can prevent cell proliferation and induce cell apoptosis. Phase Ⅰ clinical trials of new anti-tumor drugs have great risk, high fatality rate and is one of the key factors that affect the launch of the drug. Four MEK inhibitors have been approved by the U.S. Food and Drug Administration (FDA), including Trametinib, Cobimetinib, Binimetinib and Selumetinib. In this review, phase Ⅰ clinical trial data of these drugs are summarized to provide some references for other MEK inhibitors that are going to conduct phase Ⅰ clinical trials or are in clinical trials.

Key words： Mitogen activated extracellular signal-regulated kinase inhibitor Phase Ⅰclinical trials Trametinib Cobimetinib Binimetinib Selumetinib

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Yuying TIAN Hongqi

Cite this article:

GUO Yuying TIAN Hongqi. Summary of Phase Ⅰ data for MEK inhibitors approved[J]. 中国医药导报, 2021, 18(20): 193-196.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I20/193

[1] Wu PK，Becker A，Park JI. Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway [J]. Int J Mol Sci，2020，21（15）：5436.
[2] Grimaldi AM，Simeone E，Festino L，et al. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors [J]. Am J Clin Dermatol，2017，18（6）：745-754.
[3] 郝佩琪，安输，杨洋等.MEK激酶及其抑制剂的研究进展[J].中国细胞生物学学报，2015，37（10）：1425-1431.
[4] 黄慧瑶，吴大维，王海学，等.2019年中国肿瘤药物临床试验进展[J].中华肿瘤杂志，2020，42（2）：127-131.
[5] 刘晋，杨嘉莹，朱文博，等.国外创新药Ⅰ期临床试验剂量探索设计方法及其对我国的启示[J].中国新药杂志，2020，29（15）：1746-1751.
[6] Conaway MR，Petroni GR. The Impact of Early-Phase Trial Design in the Drug Development Process[J]. Clin Cancer Res，2019，25（2）：819-827.
[7] Zeiser R，Andrlova H，Meiss F. Trametinib（GSK1120212）[J]. Recent Results Cancer Res，2018，211：91-100.
[8] Infante JR，Fecher LA，Falchook GS，et al. Safety，pharmacokinetic，pharmacodynamic，and efficacy data for the oral MEK inhibitor trametinib：a phase 1 dose-escalation trial [J]. Lancet Oncol，2012，13（8）：773-781.
[9] Flaherty KT，Infante JR，Daud A，et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations [J]. N Engl J Med，2012，367（18）：1694-1703.
[10] Ribas A，Algazi A，Ascierto PA，et al. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma [J]. Nat Commun，2020，11（1）：6262.
[11] Kun E，Tsang YTM，Ng CW，et al. MEK inhibitor resistance mechanisms and recent developments in combination trials [J]. Cancer Treat Rev，2020，92：102137.
[12] Rosen LS，Lorusso P，Ma WW，et al. A first-in-human phaseⅠstudy to evaluate the MEK1/2 inhibitor， cobimetinib，administered daily in patients with advanced solid tumors[J]. Invest New Drugs，2016，34（5）：604-613.
[13] Ribas A，Gonzalez R，Pavlick A，et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF（V600）-mutated melanoma：a phase 1b study [J]. Lancet Oncol，2014，15（9）：954-965.
[14] Sullivan RJ，Hamid O，Gonzalez R，et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients [J]. Nat Med，2019，25（6）：929-935.
[15] Bendell JC，Javle M，Bekaii-Saab TS，et al. A phase 1 dose-escalation and expansion study of binimetinib（MEK162），a potent and selective oral MEK1/2 inhibitor [J]. Br J Cancer，2017，116（5）：575-583.
[16] Ascierto PA，Dummer R，Gogas HJ，et al. Update on tolerability and overall survival in COLUMBUS：landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma [J]. Eur J Cancer，2020，126：3-44.
[17] Finn RS，Ahn DH，Javle MM，et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer [J]. Invest New Drugs，2018，36（6）：1037-1043.
[18] Lowery MA，Bradley M，Chou JF，et al. Binimetinib plus Gemcitabine and Cisplatin Phase Ⅰ/Ⅱ Trial in Patients with Advanced Biliary Cancers [J]. Clin Cancer Res，2019， 25（3）：937-945.
[19] Kim JW，Lee KH，Kim JW，et al. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway：phase Ⅰb study [J]. Br J Cancer，2019，121（4）：332-339.
[20] Dummer R，Ascierto PA，Gogas HJ，et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma（COLUMBUS）：a multicentre，open-label，randomised phase 3 trial[J]. Lancet Oncol，2018，19（5）：603-615.
[21] Shirley M. Encorafenib and Binimetinib：First Global Approvals [J]. Drugs，2018，78（12）：1277-1284.
[22] Adjei AA，Cohen RB，Franklin W，et al. PhaseⅠpharmacokinetic and pharmacodynamic study of the oral， small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244（ARRY-142886）in patients with advanced cancers [J]. J Clin Oncol，2008，26（13）：2139-2146.
[23] Banerji U，Camidge DR，Verheul HM，et al. The first-in-human study of the hydrogen sulfate （Hyd-sulfate）capsule of the MEK1/2 inhibitor AZD6244（ARRY-142886）：a phaseⅠopen-label multicenter trial in patients with advanced cancer [J]. Clin Cancer Res，2010， 16（5）：1613-1623.
[24] Dombi E，Baldwin A，Marcus LJ，et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas [J]. N Engl J Med，2016，375（26）：2550-2560.
[25] Banerjee A，Jakacki RI，Onar-Thomas A，et al. A phaseⅠ trial of the MEK inhibitor selumetinib （AZD6244）in pediatric patients with recurrent or refractory low-grade glioma：a Pediatric Brain Tumor Consortium (PBTC) study [J]. Neuro Oncol，2017，19（8）：1135-1144.